Cytomegalovirus pneumonia complicating immune checkpoint inhibitors-induced pneumonitis: A case report

Omar Badran, Anton Ouryvaev, Veronika Baturov, Ayelet Shai

Research output: Contribution to journalArticlepeer-review


A 63-year-old man was hospitalized for immune check-point inhibitors (ICIs) medicated pneumonitis, secondary to treatment with pembrolizumab for non-small cell lung cancer. He was treated with high dose steroids, mycophenolate mofetil, empiric broad spectrum antibiotics and empiric trimethoprim-sulfamethoxazole and intravenous immunoglobulin. Despite the aforementioned treatment, his condition continued to deteriorate. The patient was admitted to the intensive care unit. While intubated, he underwent bronchoscopy and lavage, which was analyzed for potential infectious agents. Cytomegalovirus (CMV) pneumonia was diagnosed and treated. He passed away despite antiviral treatment and maximal supportive care. CMV infection should be suspected in patients failing to recover from toxicities of ICIs with appropriate immunosuppression.

Original languageEnglish
Article number120
JournalMolecular and Clinical Oncology
Issue number6
StatePublished - Jun 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021, Spandidos Publications. All rights reserved.


  • Cytomegalovirus pneumonia
  • Immunosuppressive therapy
  • Immunotherapy
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cytomegalovirus pneumonia complicating immune checkpoint inhibitors-induced pneumonitis: A case report'. Together they form a unique fingerprint.

Cite this